Janho dit Hreich, S.; Humbert, O.; Pacé-Loscos, T.; Schiappa, R.; Juhel, T.; Ilié, M.; Ferrari, V.; Benzaquen, J.; Hofman, P.; Vouret-Craviari, V.
Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation. Cancers 2024, 16, 2226.
https://doi.org/10.3390/cancers16122226
AMA Style
Janho dit Hreich S, Humbert O, Pacé-Loscos T, Schiappa R, Juhel T, Ilié M, Ferrari V, Benzaquen J, Hofman P, Vouret-Craviari V.
Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation. Cancers. 2024; 16(12):2226.
https://doi.org/10.3390/cancers16122226
Chicago/Turabian Style
Janho dit Hreich, Serena, Olivier Humbert, Tanguy Pacé-Loscos, Renaud Schiappa, Thierry Juhel, Marius Ilié, Victoria Ferrari, Jonathan Benzaquen, Paul Hofman, and Valérie Vouret-Craviari.
2024. "Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation" Cancers 16, no. 12: 2226.
https://doi.org/10.3390/cancers16122226
APA Style
Janho dit Hreich, S., Humbert, O., Pacé-Loscos, T., Schiappa, R., Juhel, T., Ilié, M., Ferrari, V., Benzaquen, J., Hofman, P., & Vouret-Craviari, V.
(2024). Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation. Cancers, 16(12), 2226.
https://doi.org/10.3390/cancers16122226
